REPL
resolvedReplimune Group, Inc.
Price Chart
Gap Information
Score Analysis
Model 1: Rerate Score
Model 2: Trade Probability
AI Thesis
Replimune's +110% gap represents one of the most dramatic biotech repricings possible, almost certainly driven by positive clinical readout rather than traditional earnings metrics. As a clinical-stage oncolytic virus company, the binary nature of trial data means Wall Street must entirely reassess the probability-weighted NPV of Replimune's pipeline overnight. Positive efficacy signals — particularly from their lead RP1 program in combination with checkpoint inhibitors in cutaneous squamous cell carcinoma (CSCC) — would transform the investment thesis from 'speculative platform with uncertain efficacy' to 'near-commercial oncology asset with differentiated mechanism.' The volume at 5.71x average confirms institutional repositioning, not just retail momentum. For a company that was trading in the $5 range, a doubling suggests the market is now pricing in a substantially de-risked regulatory pathway and potential peak sales that dwarf the previous enterprise value. The key question for sustained rerating is whether the data supports accelerated approval or a clear registrational path, and whether the safety profile supports combination strategies across broader tumor types — which would expand the total addressable market significantly. The oncolytic virus space has been notoriously difficult, with few successes. If Replimune has achieved meaningful response rates with a tolerable safety profile, this represents potential first-mover advantage in a modality that could complement existing immunotherapies rather than compete with them.
Analyzed by rerate-v2+glm-5.2 · Aug 3, 2026
Catalysts
- Positive efficacy data from RP1 + nivolumab combination showing meaningful improvement over standard of care
- Potential accelerated approval pathway or Breakthrough Therapy designation discussions with FDA
- Registrational trial design confirmation enabling Phase 3 initiation or completion
- Durable response rates supporting long-term survival benefit narrative
- Platform validation expanding RP2/RP3 pipeline optionality across additional tumor types
- Potential partnership interest from larger oncology companies seeking novel combination agents
Risks
- Clinical-stage company with no revenue; further dilution likely through equity offerings to fund trials
- Oncolytic virus modality has historically disappointed (Amgen's Imlygic commercial underperformance as precedent)
- Gap may attract profit-taking and short interest if data detail in full publication reveals safety concerns
- Regulatory pathway for oncolytic viruses remains uncertain; FDA may require large Phase 3 trials
- Competitive landscape in CSCC and other solid tumors is intensifying with numerous checkpoint inhibitor combinations
- Cash burn trajectory could require capital raise at these higher prices, capping upside near-term
Technical Setup
Forward Returns
Outcomes calculated Aug 11, 2026
Post-Gap Validation — 5-Day Follow-Through
Day-by-Day Price Action
| Day | Close | High | Low | Volume |
|---|---|---|---|---|
| Day 1 | $11.91 | $12.60 | $10.13 | 11.77M |
| Day 2 | $11.92 | $13.86 | $11.50 | 6.09M |
| Day 3 | $11.83 | $12.35 | $11.50 | 2.86M |
| 📍 Day 4 | $12.86 | $13.90 | $11.58 | 7.28M |
| Day 5 | $12.06 | $13.40 | $11.42 | 8.91M |
Signal Breakdown
Gap held — only 0% erased, price maintained gains
Volume sustained — only 24% decline suggests continued accumulation
Higher highs with peak close on day 4 — continued buying interest
Drew down 9.6% from gap close — significant give-back
No fundamental data to evaluate beat quality
Analysis updated Aug 11, 2026